Difficult to treat infections and antimicrobians use
PRINCIPAL INVESTIGATORS
- María Del Carmen Cabellos Mínguez
- Evelyn Shaw Perujo
- Arkaitz Imaz Vacas
CLINICAL RESEARCHERS
- Eva Benavent Palomares
- Francisco Javier Cabo Cabo
- Fe Tubau Quintano
- Raül Rigo Bonnin
- María Saumoy Linares
- Laura Soldevila Boixader
POSTDOCTORAL RESEARCHERS
- Cristina El Haj Hidalgo
PREDOCTORAL RESEARCHERS
- Eva Benavent Palomares
SCIENTIFIC SUPPORT
- Margalida Cabrer Frau
Translational Medicine
Infectious disease and transplantation
Scientific production
24
PAPERS
Average IF: 7,79
15
LED PAPERS
Average IF: 5,05
7 PUBLICATIONS IN FIRST DECILE
19 PUBLICATIONS IN FIRST QUARTILE
17 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Calvo Silveria,S;González Díaz,A;Grau,I;Marimón,JM;Cercenado,E;Quesada,MD;Casabella,A et al, Evolution of invasive pneumococcal disease by serotype 3 in adults: a Spanish three-decade retrospective study, Lancet Reg. Health-Eur., 2024;41100913-100913, doi:10.1016/j.lanepe.2024.100913
- Pérez Fernández,X;Ulsamer,A;Cámara Rosell,M;Sbraga,F;Boza Hernández,E;Moret Ruíz,E;Plata Menchaca,E et al, Extracorporeal Blood Purification and Acute Kidney Injury in Cardiac Surgery: The SIRAKI02 Randomized Clinical Trial., JAMA, 2024;332(17):1446-1454, doi:10.1001/jama.2024.20630
- Laporte Amargos,J;Carmona Torre,F;Huguet,M;Puerta Alcalde,P;Rigo Bonnin,R;Ulldemolins,M;Arnan,M et al, Efficacy of extended infusion of ß-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial., Clin. Microbiol. Infect., 2024;31(2):211-219, doi:10.1016/j.cmi.2024.10.006
- Paniagua García,M;Bravo Ferrer,JM;Pérez Galera,S;Kostyanev,T;de Kraker,M;Feifel,J;Palacios Baena,ZR et al, Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA), Clin. Microbiol. Infect., 2024;30(2):223-230, doi:10.1016/j.cmi.2023.11.008
- Paniagua García,M;Bravo Ferrer,JM;Pérez Galera,S;Kostyanev,T;de Kraker,M;Feifel,J;Palacios Baena,ZR et al, Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA), Clin Microbiol Infect, 2024;30(2):223-230, doi:10.1016/j.cmi.2023.11.008
Research highlights
PROJECTS
1 Granted competitive project
1 Ongoing competitive project
1 Started clinical trial
4 Ongoing clinical trials
1 Started non competitive project
1 Ongoing non competitive project
PUBLISHED WORKS
2 Theses
NETWORKS
CIBER-INFEC
AGAUR-SGR GRC
CSUR
Selected projects
- PI23/01031. Problemática de la infección asociada a biofilms de P. aeruginosa XDR/DTR: evaluación de alternativas terapéuticas y de su impacto en la estructura del biofilm y el resistoma. Instituto de Salud Carlos III (ISCIII). Budget: 141.250€. 2024-2026. PI: Murillo Rubio, Oscar.
- INT24/00075. CONTRATO INTENSIFICACIÓN ISCIII. Instituto de Salud Carlos III (ISCIII). Budget: 60.000€. 2025-2026. PI: Murillo Rubio, Oscar.
- PNJ24068. Efficacy of Delafloxacin alone and in combination with rifampicin against in vitro foreign-body infection caused by methicillin-resistant Staphylococcus aureus: a pharmacodynamic Study. Laboratorios Menarini SA. Budget: 72.876,25€. 2024- . PI: Oscar Murillo Rubio.
- 2023-327-2. EFFICACY AND SAFETY OF A SHORT-TERM THERAPY WITH DALBAVANCIN IN THE CHRONIC PROSTHESIS JOINT INFECTION BY GRAM-POSITIVE BACTERIA MANAGED WITH TWO-STAGE SURGICAL REVISION.. Angelini Pharma España S.L. Budget: 20.000€. 2023- . PI: Oscar Murillo Rubio.
- 2023-448-1. COHORTE MULTICÉNTRICA ENFERMEDAD DE CHAGAS. Fundació Hospital Universitari Vall d’Hebron – (VHIR). 2023- . PI: María del Carmen Cabellos Mínguez.